In this episode, David Malebranche, MD, MPH, discusses modifying ART in virologically suppressed patients, including switching ART in a patient with daily pill fatigue, switching ART to avoid comorbidities and simplifying ART in the context of known multidrug resistance. The overview will include analyses from:The ATLAS and FLAIR studies in which long-acting intramuscular CAB + RPV was initiated after initial virologic suppression with oral therapyD:A:D study data that found cumulative use of RTV-boosted DRV, but not RTV-boosted ATV, was independently associated with a small but progressively increasing risk of CVD eventsThe SWORD-1 and -2 evaluating the switch to DTG + RPV vs continuation of baseline ART in virologically suppressed adultsThe TANGO study that compared switching to DTG/3TC vs continuing a TAF-based 3-drug regimenThe DAWNING study that showed favorable outcomes for treatment-experienced patients switched to DTG containing regimens with an M184V mutation, whether the regimen contained emtricitabine or lamivudine or notStudy 380-4030 that showed noninferiority in maintenance of viral suppression when switching to BIC/FTC/TAF from DTG + FTC/(TAF or TDF)BRAAVE 2020 that evaluated the impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWHIn addition, Dr. Malebranche reviews current recommendations by the DHHS regarding considerations when switching regimens in virologically suppressed patients and switching regimens in patients with viral suppression and drug resistance.Presenter:David J. Malebranche, MD, MPHInternal Medicine PhysicianHIV/Sexual Health SpecialistClinician, AIDS Healthcare Foundation (AHF) Medical ClinicAtlanta, GeorgiaFollow along with the slides at:https://bit.ly/3kseOqkContent based on an online CME program supported by an educational grant from ViiV Healthcare.Link to full program:https://bit.ly/3ux6FF8